Review
Food Science & Technology
Carlo Baraldi, Flavia Lo Castro, Raffaele Ornello, Simona Sacco, Luca Pani, Simona Guerzoni
Summary: OnabotulinumtoxinA (BT-A) is a drug used for preventive treatment of chronic migraine. Its exact mechanism of action is still debated, but it is known to inhibit the release of inflammatory mediators and reduce activation of nerve fibers. Clinical trials have shown its efficacy, and recent findings have improved understanding of its pharmacological actions. This review summarizes the available data on BT-A and discusses its role in chronic migraine treatment.
Article
Food Science & Technology
Enrique Martinez-Pias, Angel L. Guerrero, Alvaro Sierra, Javier Trigo, David Garcia-Azorin
Summary: Chronic migraine patients with daily headaches do not have a worse response to OnabotulinumtoxinA treatment, while patients with higher headache frequency at baseline are more likely to show a better response to this treatment.
Article
Medicine, General & Internal
Laura Papetti, Ilaria Frattale, Fabiana Ursitti, Giorgia Sforza, Gabriele Monte, Michela Ada Noris Ferilli, Samuela Tarantino, Martina Proietti Checchi, Massimiliano Valeriani
Summary: This study aims to describe the experience with the use of OnabotulinumtoxinA (OBT-A) in the treatment of chronic migraine in adolescents. The results show that OBT-A can reduce the frequency and intensity of headache episodes and has a good safety profile. These data support the use of OBT-A in the treatment of childhood migraine.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Ali Zandieh, Fred Michael Cutrer
Summary: The study found that increasing the dose of onabotulinumtoxinA is associated with a decrease in headache and severe headache days, with 200 units showing better efficacy compared to 150 units. Future randomized clinical trials are needed to confirm the dose-dependent response to onabotulinumtoxinA.
Article
Clinical Neurology
Igor Wilderman, Deborah Tallarigo, Olga Pugacheva-Zingerman
Summary: OBT-A is a well-studied prophylactic treatment for chronic migraine, with evidence supporting its effectiveness. This study explored patient experiences and perceptions of OBT-A treatment, revealing common themes among patients who received treatment and those who did not proceed, providing insights into potential barriers to treatment initiation or continuation. Understanding patients' perspectives is crucial for clinical practice and decision-making.
Article
Food Science & Technology
Andreas A. A. Argyriou, Emmanouil V. V. Dermitzakis, Georgia Xiromerisiou, Michail Vikelis
Summary: This study aimed to evaluate the effectiveness of combining dual therapy with BTX and anti-CGRP MAbs in treatment-refractory CM patients. Retrospective review of medical files of 19 patients showed that dual therapy was effective and associated with significant clinical improvement in the majority of cases, with favorable safety and tolerability.
Article
Clinical Neurology
Todd J. Schwedt, Joseph G. Hentz, Soma Sahai-Srivastava, Nicole M. Spare, Vincent T. Martin, Christina Treppendahl, Kathleen Digre, Nathan L. Bennett, Marius Birlea, David Watson, Natalia Murinova, Teri Robert, David W. Dodick
Summary: The study described headache characteristics, medication use, disability, and quality of life in patients with chronic migraine (CM) and medication overuse headache (MOH) from the United States. Findings showed a significant burden on patients with CM and MOH, with higher headache frequency associated with greater impact on functioning, pain interference, and quality of life.
Article
Clinical Neurology
Sanjay Cheema, Anker Stubberud, Khadija Rantell, Parashkev Nachev, Erling Tronvik, Manjit Matharu
Summary: This study examined the relationship between new daily persistent headache (NDPH) and transformed chronic daily headache (T-CDH), and found significant differences in gender, symptoms, and treatment response between the two. Additionally, cluster analysis identified three subtypes of NDPH, providing guidance for further research.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Pharmacology & Pharmacy
Fan Cheng, Fayyaz Ahmed
Summary: This article evaluates the mechanisms of action, efficacy, safety, and adverse events of OnabotulinumtoxinA in the prophylaxis of chronic migraine. Studies indicate that OnabotulinumtoxinA is safe and effective in improving symptoms in patients with chronic migraine.
EXPERT OPINION ON DRUG SAFETY
(2021)
Article
Clinical Neurology
Karthik Nagaraj, Diana Y. Wei, Francesca Puledda, Hsing-Yu Weng, Sadaf Waheed, Nicolas Vandenbussche, Jonathan J. Y. Ong, Peter J. Goadsby
Summary: This study compared the clinical phenotype of chronic migraine (CM) patients to patients with the chronic migraine subtype of new daily persistent headache (NDPH-CM). The UK cohort showed that CM patients had an earlier age of first headache onset, more associated migrainous symptoms, and a higher prevalence of a family history of headache compared to NDPH-CM patients. No differences were found in the US cohort. Osmophobia and older age at presentation were negative predictors of NDPH-CM.
Review
Clinical Neurology
Simona Guerzoni, Carlo Baraldi, Luca Pani
Summary: Chronic migraine is a challenge for physicians, and despite the introduction of monoclonal antibodies targeting CGRP, some patients still do not experience complete relief. The combination of onabotulinumtoxinA and anti-CGRP mAbs may offer a reliable option for these patients. However, there is limited evidence and regulatory restrictions regarding this combination therapy, calling for further well-designed studies and pharmacoeconomic analysis.
NEUROLOGICAL SCIENCES
(2022)
Review
Neurosciences
Joseph H. Talbet, Ayman G. Elnahry
Summary: Botulinum toxin (BT) is a neurotoxin used for the treatment of conditions associated with increased muscle tone, smooth muscle hyperactivity, salivation, sweating, and allergies. Specifically, onabotulinumtoxinA is commonly used for the treatment of chronic pain disorders.
JOURNAL OF INTEGRATIVE NEUROSCIENCE
(2022)
Article
Clinical Neurology
Laszlo Mechtler, Nicolas Saikali, Jennifer McVige, Olivia Hughes, Alexandra Traut, Aubrey Manack Adams
Summary: This study aimed to assess the safety and effectiveness of combining onabotulinumtoxinA with CGRP mAbs for the preventive treatment of chronic migraine. The results showed that the combination treatment was effective in reducing monthly headache days and was safe and well-tolerated. Lack of insurance coverage was the most common reason for discontinuation of the treatment.
FRONTIERS IN NEUROLOGY
(2022)
Article
Food Science & Technology
Angelo Torrente, Laura Pilati, Salvatore Di Marco, Simona Maccora, Paolo Alonge, Lavinia Vassallo, Antonino Lupica, Serena Coppola, Cecilia Camarda, Nadia Bolognini, Filippo Brighina
Summary: This study found that multisensory integration is modified in chronic migraine, and onabotulinumtoxinA is effective in preventing chronic migraine and restoring multisensory processing.
Article
Clinical Neurology
Baraldi Carlo, Raffaele Ornello, Valentina Favoni, Simona Sacco, Valeria Caponnetto, Giulia Pierangeli, Pani Luca, Sabina Cevoli, Simona Guerzoni
Summary: This study found that stopping BT-A led to significant worsening in patients with chronic migraine, particularly in those not receiving other preventive treatments besides BT-A. Patients experiencing over 30% worsening in headache days after BT-A withdrawal typically had longer histories and higher pain indicators.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Serena L. Orr, Marielle A. Kabbouche, Paul S. Horn, Hope L. O'Brien, Joanne Kacperski, Susan LeCates, Shannon White, Jessica Weberding, Mimi N. Miller, Scott W. Powers, Andrew D. Hershey
Review
Clinical Neurology
Serena L. Orr, Marielle A. Kabbouche, Hope L. O'Brien, Joanne Kacperski, Scott W. Powers, Andrew D. Hershey
NATURE REVIEWS NEUROLOGY
(2018)
Article
Clinical Neurology
Keren Armoni Domany, Hadas Nahman-Averbuch, Christopher D. King, Thomas Dye, Yuanfang Xu, Monir Hossain, Andrew D. Hershey, Narong Simakajornboon
Editorial Material
Clinical Neurology
Scott B. Turner, Elizabeth K. Rende, Christina L. Szperka, Andrew D. Hershey, Amy A. Gelfand
Article
Clinical Neurology
Kevin A. Hommel, Julia Carmody, Andrew D. Hershey, Christina Holbein, Marielle Kabbouche-Samaha, James Peugh, Scott Powers
Article
Clinical Neurology
Andrew D. Hershey, Tamar Lin, Yaron Gruper, Dagan Harris, Alon Ironi, Thomas Berk, Christina L. Szperka, Frank Berenson
Summary: The study suggests that REN may provide a safe and effective non-pharmacological alternative for acute treatment in adolescents, addressing the limitations and side effects associated with pharmaceutical treatments.
Article
Clinical Neurology
Hadas Nahman-Averbuch, Priya L. Thomas, Victor J. Schneider, Leigh Ann Chamberlin, James L. Peugh, Andrew D. Hershey, Scott W. Powers, Robert C. Coghill, Christopher D. King
Summary: This study compared spatial pain modulation capabilities between adolescents with migraine and healthy controls. While altered ascending nociceptive processing of mechanical stimuli at the neck was found in adolescents with migraine, endogenous pain modulatory mechanisms were functional and not altered. Impairments in inhibitory control may not be involved in migraine pathophysiology in pediatric patients regardless of stimulus location.
Editorial Material
Clinical Neurology
Andrew D. Hershey, Cynthia E. Armand, Thomas Berk, Rebecca Burch, Dawn C. Buse, Carrie Dougherty, Michael J. Marmura, Mia T. Minen, Jennifer Robblee, Heidi B. Schwarz
Editorial Material
Clinical Neurology
Hadas Nahman-Averbuch, Andrew D. Hershey, James L. Peugh, Christopher D. King, Ashley M. Kroon Van Diest, Leigh Ann Chamberlin, Marielle A. Kabbouche, Joanne Kacperski, Robert C. Coghill, Scott W. Powers
Article
Clinical Neurology
Marina Vives-Mestres, Amparo Casanova, Andrew D. Hershey, Serena L. Orr
Summary: In this study, individuals with chronic migraine exhibited distinct patterns of peak attack severity from day-to-day. While overall higher perceived stress was associated with higher peak severity, there were significant variations in this relationship between individuals.
Article
Anesthesiology
Andrew D. Hershey, Samantha Irwin, Liron Rabany, Yaron Gruper, Alon Ironi, Dagan Harris, Roni Sharon, Jennifer McVige
Summary: Remote electrical neuromodulation (REN) is a novel nonpharmacological treatment that shows higher efficacy than standard-care medications for the acute treatment of migraine in adolescents. REN group achieved better pain relief and consistency compared to the medication group.
Article
Clinical Neurology
Hadas Nahman-Averbuch, Victor J. Schneider, Gregory R. Lee, James L. Peugh, Andrew D. Hershey, Scott W. Powers, Massimiliano de Zambotti, Robert C. Coghill, Christopher D. King
Summary: This case-control study examines the measures of subjective and objective sleep difficulties and their effects on amygdalar connectivity in adolescents with migraine. The study found that adolescents with migraine have greater connectivity between the amygdala and areas involved in sensory, affective, and cognitive aspects of pain. However, these differences in functional connectivity were not mediated by measures of sleep difficulties.
Letter
Clinical Neurology
Daniel N. Lax, Kelly Sitterle, Joanne Kacperski, Andrew D. Hershey, Marielle Kabbouche
Article
Clinical Neurology
Brooke L. Reidy, Emily J. Riddle, Scott W. Powers, Shalonda K. Slater, Joanne Kacperski, Marielle Kabbouche, James L. Peugh, Andrew D. Hershey
Summary: This retrospective cohort study examined the factors related to initial clinical outcomes among treatment-seeking youth with continuous headache. The results showed that a significant percentage of youth experienced improvements in headache status after treatment. Those with worse treatment outcomes had a longer history of continuous headache, higher disability, higher likelihood of new daily persistent headache, and higher likelihood of feeling depressed.
Article
Clinical Neurology
Danielle J. Kellier, Blanca Marquez de Prado, Dana Haagen, Philip Grabner, Nichelle Raj, Lara Lechtenberg, Gerardo Velasquez, Jesse Y. Hsu, John T. Farrar, Andrew D. Hershey, Christina L. Szperka
Summary: There is moderate agreement between self-report and diagnostic guidelines for migraine day in children and adolescents.